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Abstract: Hyperglycemia is a major risk factor for both the microvascular and macrovascular 
complications in patients with type 2 diabetes. This review summarizes the cardiovascular results 
of large outcomes trials in diabetes and presents new evidence on the role of hyperglycemia, with 
particular emphasis on postprandial hyperglycemia, in adverse cardiovascular outcomes in 
patients with type 2 diabetes. Treatment options, including the new dipeptidyl peptidase-4 
inhibitors and glucagon-like peptide-1 mimetics that primarily target postprandial hypergly-
cemia, are also discussed. Hyperglycemia increases cardiovascular mortality, and reducing 
hyperglycemia lowers cardiovascular risk parameters. Control of both fasting and postprandial 
hyperglycemia is necessary to achieve optimal glycated hemoglobin control. Therefore, anti-
hyperglycemic agents that preferentially target postprandial hyperglycemia, along with those 
that preferentially target fasting hyperglycemia, are strongly suggested to optimize individual 
diabetes treatment strategies and reduce complications.
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Introduction
Several landmark clinical trials have convincingly demonstrated that hyperglycemia is 
associated with the microvascular complications of diabetes.1–3 These trials, along with 
epidemiological evidence, have provided the basis for treatment targets and algorithms 
recommended by the American Diabetes Association (ADA), the American Association 
of Clinical Endocrinologists (AACE), and the European Association for the Study of 
Diabetes (EASD).4–6 Adequacy of glycemic control is almost universally assessed by 
glycated hemoglobin (HbA1c) – a measure of hemoglobin glycation over the erythro-
cyte life span that is proportional to the mean plasma glucose level over the preceding 
2 to 3 months. An HbA1c 7% is recommended by the ADA/EASD and 6.5% by the 
AACE.4–6 The mean value for individuals with normal glucose tolerance is 5.0% (upper 
limit of normal is 6.0%). HbA1c can be communicated with patients using estimated 
average glucose (eAG; HbA1c 5% = eAG 5.4 mmol/L, 97 mg/dL), so that they better 
understand how their blood glucose monitor readings are related to HbA1c.4
In addition to HbA1c, patients and physicians usually monitor and treat fasting plasma 
glucose (FPG) levels, but ignore or de-emphasize postprandial glucose (PPG) levels. 
There is no evidence that fasting hyperglycemia is more deleterious than postprandial 
hyperglycemia. Recent evidence, however, strongly suggests that control of postprandial 
hyperglycemia may be necessary to achieve HbA1c targets 7%.7 Considerable data 
have accumulated indicating that elevated PPG levels, even in the absence of fasting 
hyperglycemia, increase the risk for cardiovascular (CV) disease (CVD). This article Vascular Health and Risk Management 2010:6 146
Aryangat and Gerich Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
discusses and updates epidemiological and experimental 
studies linking postprandial hyperglycemia to CVD, and 
therapeutic approaches, both available and in development.
Hyperglycemia and CVD
In people with type 2 diabetes, macrovascular disease, in par-
ticular CVD, is the major source of morbidity and mortality. 
The pathogenesis of CVD is complex and multifactorial. 
Smoking, obesity, dyslipidemia, and hypertension were 
considered the major “traditional” risk factors. Now diabe-
tes itself is considered an important independent risk fac-
tor.8 Having diabetes increases the risk for CVD mortality 
more than two-fold.9 For example, in the INTERHEART study, 
a case-control study that assessed risk factors of coronary 
artery disease (CAD) worldwide in nearly 30,000 subjects, 
diabetes increased the odds ratio of having an acute myocar-
dial infarction (MI) to 4.26 (99% confidence interval [CI], 
3.51 to 5.18) in women and to 2.67 (99% CI, 2.36 to 3.02) in 
men (Table 1), making diabetes as important a risk factor as 
smoking, hypertension, obesity, and dyslipidemia.10
Numerous epidemiological studies have demonstrated a 
correlation between risk for CVD and plasma glucose levels 
(both fasting and postprandial) or HbA1c values.11 The rela-
tionship between PPG and CV events persists even in the con-
text of HbA1c levels in the nondiabetic range.11,12 Moreover, the 
Funagata Diabetes Study showed that the cumulative survival 
rates from CVD of impaired glucose tolerance (IGT) and 
diabetes were reduced comparably, whereas the cumulative 
survival rate from CVD of impaired fasting glucose (IFG) 
was not.13 This suggests that IGT (or postprandial glycemia) 
is a more important CVD risk factor than IFG.
Epidemiological data suggest a strong link between CV 
risk and glucose control, but by nature of study design, can-
not determine causality. Controlled clinical trials can deter-
mine causality and have examined the effects of glycemic 
control on vascular complications. The United Kingdom 
Prospective Diabetes Study (UKPDS),1 the Diabetes Control 
and Complications Trial (DCCT),3 the Action to Control 
Cardiovascular Risk in Diabetes (ACCORD),14 and the Action 
in Diabetes and Vascular Disease: Preterax and Diamicron 
Modified Release Controlled Evaluation (ADVANCE)2 were 
landmark controlled clinical trials that evaluated the benefits 
of intensive glucose control on diabetes complications. The 
UKPDS demonstrated a 25% risk reduction for microvascular 
complications (P = 0.0099) and a 16% risk reduction for MI 
(P = 0.052) in intensively treated patients.1 Moreover, during 
a 10-year poststudy monitoring period, the UKPDS follow-up 
data demonstrated a persistent 15% risk reduction for MI 
(P = 0.01) and a 13% risk reduction for all-cause mortality 
(P = 0.007; Figure 1) despite a convergence in glycemic 
control levels between treatment groups.15
The DCCT follow-up study yielded a similar finding. 
The DCCT consisted of 1441 patients with type 1 diabetes 
randomized to intensive or conventional therapy for a mean 
of 6.5 years – 1983 through 1993.3,16 Ninety-three percent 
of patients from the DCCT were followed until Febru-
ary 1, 2005, (mean 17-year follow-up) in the observational 
Epidemiology of Diabetes Interventions and Complications 
(EDIC) study. Intensive treatment reduced the risk of any 
CVD event by 42% (95% CI, 9% to 63%; P = 0.02) and 
the risk of nonfatal MI, stroke, or death from CVD by 57% 
(95% CI, 12% to 79%; P = 0.02).
The ACCORD14 and ADVANCE2 trials evaluated inten-
sive blood glucose control below the current recommended 
levels of HbA1c and its impact on CV events. The ACCORD 
study consisted of 10,251 patients with type 2 diabetes with 
a median baseline HbA1c of 8.1% who were given intensive 
therapy to target HbA1c below 6% versus standard therapy 
(HbA1c = 7.0% to 7.9%). Thirty-five percent of patients had 
history of a previous CV event. The intensively treated arm 
of the study was terminated early because of higher mortality 
of 257 patients in this treatment group versus 203 patients in 
the standard therapy group. However, nonfatal MI occurred 
less often in the intensive group than in the standard group 
(P = 0.004). Although overall difference in macrovascular 
events in ACCORD was not statistically significant between 
intensive and standard therapy, patients in the intensive 
Table 1 Association of risk factors with acute myocardial infarc-
tion in men and women
Risk factor Sex Odds ratio (99% CI)a
Diabetes F 4.26 (3.51–5.18)
M 2.67 (2.36–3.02)
Hypertension F 2.95 (2.57–3.39)
M 2.32 (2.12–2.53)
Current smoking F 2.86 (2.36–3.48)
M 3.05 (2.78–3.33)
Abdominal obesity F 2.26 (1.90–2.68)
M 2.24 (2.03–2.47)
ApoB/ApoA1 ratiob F 4.42 (3.43–5.70)
  M 3.76 (3.23–4.38)
aAdjusted for age, sex, and geographic area.
bApoB/ApoA1 ratio as an index of dyslipidemia.
Adapted from The Lancet, 364,  Yusuf S, Hawken S, Ôunpuu S, et al; for the iNTeRHeART 
Study Investigators. Effect of potentially modifiable risk factors associated with 
myocardial infarction in 52 countries (the iNTeRHeART study): case-control study, 
937–952.10 Copyright © (2004), with permission from elsevier.
Abbreviations: F, female; M, male.Vascular Health and Risk Management 2010:6 147
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therapy arm with no history of prior CV events or whose 
baseline HbA1c level was 8% had significantly fewer fatal 
or nonfatal CV events than the standard therapy arm. In these 
subgroups, intensive lowering of HbA1c was beneficial.14
The ADVANCE trial2 studied 11,140 patients with type 2 
diabetes randomized to receive standard therapy or gliclazide 
plus other medications to achieve HbA1c of 6.5% in the 
intensive control arm. With a median 5-year follow-up, mean 
HbA1c was lower in the intensive control group (6.5%) than in 
the standard control group (7.3%). Intensive control reduced 
the incidence of combined major macro- and microvascular 
events (18.1% versus 20.0% with standard control; hazard 
ratio [HR], 0.90; 95% CI, 0.82 to 0.98; P = 0.01), as well as that 
of major microvascular events (9.4% versus 10.9%; HR, 0.86; 
95% CI, 0.77 to 0.97; P = 0.01), primarily because of a reduc-
tion in the incidence of nephropathy (4.1% versus 5.2%; HR, 
0.79; 95% CI, 0.66 to 0.93; P = 0.006). The ADVANCE trial, 
while positive for microvascular complications, had an event 
rate too low to have the statistical power to show a benefit of 
intensive glucose control on macrovascular complications.
The Veterans Affairs Diabetes Trial (VADT)17 randomized 
1791 patients with type 2 diabetes who had suboptimal 
control on oral medications or insulin with a median HbA1c of 
8.4% for intensive glucose control or standard therapy, with a 
goal of an absolute reduction of 1.5% HbA1c in the intensive 
versus standard therapy group. A major CV event, the primary 
outcome, occurred in 264 patients in the standard therapy 
group and 235 patients in the intensive therapy group (HR 
in the intensive therapy group, 0.88; 95% CI, 0.74 to 1.05; 
P = 0.14). The incidence of primary outcome was not sig-
nificantly lower in the intensive arm, but a subgroup analysis 
indicated that patients who had diabetes less than ∼12 years 
derived CV benefit from intensive glycemic control.18 Also, 
an embedded ancillary study within the main VADT showed 
that patients with previous history of increased baseline 
coronary or aortic calcium scores benefited less compared 
with patients who had low calcium scores.18
Together, the ACCORD,14 ADVANCE,2 and VADT17 
studies showed significant CV benefit in patients who had 
lower baseline HbA1c, no prior history of CAD, and shorter 
history of diabetes. Both the DCCT and UKPDS primary 
intervention studies also demonstrated long-term macrovas-
cular benefits (10 year follow-up).15,16 Taken together, these 
studies illustrate that intensive glycemic control early in the 
course of diabetes is important in achieving CV benefit and 
provides guidance in terms of stratification of patients’ target 
glycemic control. Thus, achieving a goal of HbA1c 7% is 
recommended, but a less intense target should be planned for 
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Figure 1 Significant relative risk reduction in microvascular disease and any diabetes end point continued during 10 years of post-trial follow-up. Significant emergent risk 
reductions in myocardial infarction and all-cause mortality were observed only with extended follow-up.1,15
Adapted from The Lancet, 352, UK Prospective Diabetes Study (UKPDS) Group, intensive blood-glucose control with sulphonylureas or insulin compared with conventional 
treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), 837–853.1 Copyright © (1998), with permission from elsevier.Vascular Health and Risk Management 2010:6 148
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patients with history of severe CVD, severe hypoglycemia, or 
advanced microvascular or macrovascular disease complica-
tions. In addition to addressing diabetes control, physicians 
must optimize other modifying factors of CVD, including 
blood pressure, hyperlipidemia, obesity, smoking cessation, 
regular exercise, and healthy diet.18 In the future, develop-
ment of a risk profile and stratification will be important 
in customizing and guiding each patient’s glycemic target 
and optimizing the benefits of intensive glucose control.
Mechanisms of hyperglycemia-
induced CV damage
Acute hyperglycemia has been linked to endothelial dys-
function. Monnier et al19 reported that the urinary excretion 
rate of 8-iso-prostaglandin F2α, a marker of oxidative stress, 
correlated best with the glycemic variability assessed from 
the mean amplitude of glycemic excursions. To add another 
level of complexity, Ceriello et al20 showed that not only 
was hyperglycemia associated with endothelial dysfunction 
in patients with and without type 2 diabetes, but also that 
oscillating glucose levels in 6-hour increments led to even 
greater dysfunction over time. Other studies also provided 
evidence that postprandial fluctuations, in addition to abso-
lute increases in glycemia, contribute to oxidative stress 
and endothelial dysfunction.21–23 Endothelial dysfunction 
seems to be affected via the vascular glycocalyx (an extra-
cellular matrix of endothelial cell-derived proteoglycans, 
glycoproteins, and absorbed plasma proteins that act as a 
mechanosensor/mechanotransducer of blood flow and vas-
cular shear stress) in a predominantly nitric oxide-dependent 
manner that promotes endothelial response to stimuli.24–26 
Nieuwdorp et al26 utilized several techniques (eg, hypergly-
cemic clamp, flow-mediated dilation, glycocalyx tracers, and 
laboratory analytical tests) to assess endothelial function and 
coagulation parameters after hyperglycemic challenge in 10 
healthy males. After glucose infusion, glycocalyx volume 
was decreased, mechanotransduction of flow-dependent 
arterial dilation was attenuated, and levels of prothrombin 
activation fragment F1 + 2, a factor that initiates coagulation 
cascades, were increased during hyperglycemia. Moreover, 
reducing PPG has been reported to improve endothelial 
dysfunction.23 Oxidative stress caused by acute PPG spikes 
can contribute to macrovascular damage through oxidation 
of low-density lipoprotein, exacerbation of endothelial dys-
function, and other proatherogenic mechanisms. An overview 
of the complex interaction between factors that contribute 
to macrovascular complications of diabetes is presented in 
Figure 2.11,27
Management of postprandial 
hyperglycemia
Postprandial glucose control is the rate-limiting step when 
optimizing blood glucose levels, as demonstrated in the study 
by Woerle et al.7 This prospective interventional trial assessed 
the relative contributions of FPG and PPG in achieving recom-
mended HbA1c goals. There were 164 patients with type 2 dia-
betes with HbA1c levels 7.5% (mean 8.7% ± 0.1) with target 
reductions of FPG to 5.6 mmol/L (100 mg/dL) and PPG 
at 90 minutes to 7.8 mmol/L (140 mg/dL). The study 
showed that when FPG (but not PPG) was at target, only 64% 
of patients achieved HbA1c 7%, whereas when both FPG and 
PPG were at target, 94% achieved HbA1c 7%. FPG values 
did not differ in patients with HbA1c above or below 7%. PPG 
accounted for ∼90% of HbA1c values when HbA1c was 6.2%, 
but only ∼40% when HbA1c was 8.9%.7 These results further 
illustrate the importance of PPG in achieving better control 
of diabetes, consistent with an earlier study conducted by 
Monnier et al.28 Most recently, results from the 4-T trial 
(Treating to Target in Type 2 Diabetes) indicated preprandial 
treatment with a rapid-acting insulin analogue resulting in 
significant decreases in PPG (–85 ± 59 mg/dL) compared 
with basal and biphasic insulin regimens (–61 ± 58 mg/dL and 
–67 ± 50 mg/dL, respectively).29 However, while preprandial 
treatment with a rapid-acting insulin analogue resulted in 
significant reductions in HbA1c from baseline (–1.4% ± 0.1), 
comparisons with basal and biphasic insulin regimens were 
not significantly different (–1.3% ± 0.1 and –1.2% ± 0.1, 
respectively). It is interesting to note that no differences were 
found in FPG levels among the treatment groups.29
Furthermore, randomized controlled trials with agents 
that primarily target postprandial hyperglycemia have 
demonstrated CV benefit. The Study to Prevent Non-
Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial 
showed that treating postprandial hyperglycemia with acar-
bose in patients with IGT reduced CV events.30 PPG levels 
seen in diabetic patients correlate with carotid intima-media 
thickness (CIMT),31 and treatment with antihyperglycemic 
agents such as nateglinide and acarbose – which target post-
prandial glycemia – reduces progression of CIMT.32,33 In addi-
tion, optimal control of postprandial hyperglycemia has been 
associated with improved coronary blood flow34 as well as 
possible reversal of myocardial perfusion abnormalities.35
ADA, iDF, and AACe recommendations
The ADA in its Standards of Medical Care in Diabetes–20094 
acknowledges that elevated PPG values are associated with 
increased CV risk – independent of FPG – and that the relative Vascular Health and Risk Management 2010:6 149
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contribution of postprandial hyperglycemia to HbA1c is greater 
at HbA1c levels that are closer to 7%. The ADA recommends 
that individuals who have preprandial glucose values within 
target, but have HbA1c values above target, should monitor 
PPG 1 to 2 hours after the start of a meal. Treatment aimed 
at reducing PPG values to 10 mmol/L (180 mg/dL) will 
likely lower HbA1c and may improve outcomes.4
The International Diabetes Federation (IDF) recom-
mends that patients with diabetes manage their HbA1c 
levels to be 6.5% by addressing both FPG and PPG. 
The guidelines recommend that PPG levels not exceed 
7.8 mmol/L (140 mg/dL) during the 2 hours postmeal. 
The frequency of self-monitoring to track PPG levels should 
be planned on an individual basis.36 AACE guidelines are 
similar to those of the IDF, suggesting HbA1c 6.5%, FPG   
6 mmol/L (110 mg/dL), and 2-hour PPG 7.8 mmol/L 
(140 mg/dL).5
Treatment considerations
Nonpharmacologic interventions
Lifestyle management, including medical nutrition therapy 
(well-balanced diet), physical activity, and weight control, is 
recommended for all patients with type 2 diabetes. Decreases 
in HbA1c of approximately 1% to 2% have been demonstrated 
in randomized controlled clinical trials and observational 
studies evaluating medical nutrition therapy.37 Of note, 
a recent systematic review and analysis by Boling et al38 
echoed previous suggestions that low-carbohydrate (ie, 40% 
energy from carbohydrates), rather than “well-balanced,” diets 
lead to better glycemic control (HbA1c decreases of –0.9% 
Figure 2 Mechanisms by which hyperglycemia induces mitochondrial overproduction of superoxide and activates 4 major pathways of hyperglycemic damage.11,27
Copyright © 2005 American Diabetes Association from Diabetes. 2005;54:1615–1625.27   Adapted with permission from the American Diabetes Association.Vascular Health and Risk Management 2010:6 150
Aryangat and Gerich Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
to –1.5%) and may be the most efficacious dietary strategy 
for reducing obesity-related metabolic disease complications. 
Similarly, a meta-analysis by Barclay et al39 indicated that low 
glycemic index and glycemic load diets result in reduced risk 
for type 2 diabetes and heart disease. The most recent and 
notable example of the advantages of weight loss, conferred 
by increased physical activity and low-calorie/low-fat diets,40 
are results from the 10-year follow-up of the Diabetes Pre-
vention Program (DPP) Outcomes Study.41 This follow-up, 
prospective analysis included 2766 patients at high risk for 
developing type 2 diabetes from the initial DPP trial who 
received standard medical information regarding health 
risks and type 2 diabetes and placebo, metformin, or inten-
sive lifestyle intervention (for details, consult the published 
description of the latter group40). The most significant findings 
of this study were that the placebo-adjusted incidences of a 
type 2 diabetes diagnosis at 10 years showed 34% and 18% 
reductions for the intensive lifestyle intervention and metfor-
min groups, respectively.41 Interestingly, while patients in the 
lifestyle intervention and metformin groups tended to lose 
weight initially, mean weight of the 3 treatment groups tended 
to converge at 10 years, though at a range of 0 to –2.5 kg 
change from baseline for all groups.41 However, clinicians 
clearly recognize that lifestyle interventions in most patients 
are largely ineffective without intensive supervision because it 
is difficult for most patients to change their lifestyle or main-
tain positive lifestyle changes. It has been shown that patients 
with higher perceived and actual risks of developing diabetes 
did not intend to adopt healthier lifestyle behaviors more 
readily than those with lower perceived and actual risks,42 
though if followed closely with physician monitoring and 
clinical support, patients can indeed reap the benefits (eg, risk 
reduction of developing diabetes) of such alterations.39–41,43 
Unfortunately, intensive treatment approaches are costly44,45 
making them unpopular amidst the current economic crises 
worldwide and ever rising health care costs in the United 
States. Some efforts to reduce costs by using community 
resources or motivational techniques have shown promising 
results,46,47 but are far from large-scale implementation.
Surgical intervention
Obesity, superimposed on a genetic β-cell defect, is the 
main cause for the increased prevalence of type 2 diabetes.48 
Bariatric surgery is a growing weight loss option for obese 
people who have failed lifestyle and diet pill interventions. 
The National Institutes of Health (NIH) guidelines require 
bariatric surgery candidates to have a body mass index 
(BMI) 40 kg/m2 (severe obesity) or a BMI between 35 and 
39.9 kg/m2 with a serious obesity-related health problem such 
as type 2 diabetes, coronary heart disease, or severe sleep 
apnea.49 This is unconscionable considering some health-
care providers believe that the NIH guideline should be less 
restrictive, given the considerable health and cost benefits 
of bariatric surgery.50
Bariatric surgery has dramatic effects on glycemic 
control. For example, in a randomized controlled trial with 
60 obese patients (BMI 30 and 40 kg/m2) with type 2 
diabetes 2 years, half the patients had laparoscopic adjust-
able gastric banding with conventional diabetes care; the 
other half had conventional diabetes therapy with lifestyle 
changes. Among patients who completed the 2-year follow-
up, 73% in the surgical group versus 13% in the control 
group achieved remission of type 2 diabetes.51 A 10-year 
study comparing conventional (nonsurgical) treatment with 
bariatric surgery showed recovery from diabetes in 72% of 
patients in the bariatric surgical group, compared with 21% 
in the nonsurgical group after 2 years.52 Furthermore, a 
cost-analysis study indicates that there is a return on invest-
ment in 2 to 5 years postsurgery with respect to the costs 
associated with comorbidities in morbidly obese patients, 
including those with type 2 diabetes, CAD, hypertension, 
and sleep apnea.50 While this strategy is gaining further 
popularity among patients with BMI 35 kg/m2, long-term 
studies among the dysglycemic subpopulation are needed to 
ascertain whether this strategy can be applied universally to 
obese patients with postprandial hyperglycemia.
Pharmacologic interventions
The classes of drugs for the treatment of type 2 diabe-
tes that primarily target postprandial hyperglycemia are 
summarized in Table 2.6,11,53 The 2 newest classes of anti-
diabetic agents – dipeptidyl peptidase-4 (DPP-4) inhibi-
tors and glucagon-like peptide-1 (GLP-1) analogs – are 
incretin-based therapies. The incretin hormones, GLP-1 
and glucose-dependent insulinotropic polypeptide (GIP), 
are released from the small intestine during absorption 
of meals and increase pancreatic secretion of insulin.54 
GLP-1, but not GIP, suppresses glucagon release from the 
pancreatic α-cells. In type 2 diabetes, incretin hormone 
function is impaired,54 resulting in less insulin release and 
more glucagon secretion after meals.55 More glucose enters 
the circulation, but there is less efficient glucose removal, 
higher plasma glucose levels, and hence, acute oxidative 
stress.22,55 Disease-related complications associated with 
oxidative stress may be reduced with agents that target post-
prandial hyperglycemia.Vascular Health and Risk Management 2010:6 151
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g
e
d
 
b
l
o
o
d
 
g
l
u
c
o
s
e
–
l
o
w
e
r
i
n
g
 
 
e
f
f
e
c
t
s
 
i
f
 
u
s
e
d
 
c
o
n
c
o
m
i
t
a
n
t
l
y
 
w
i
t
h
 
 
g
e
m
fi
b
r
o
z
i
l
 
2
)
 
N
a
t
e
g
l
i
n
i
d
e
 
 
(
S
t
a
r
l
i
x
®
,
 
N
o
v
a
r
t
i
s
 
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
s
 
 
C
o
r
p
o
r
a
t
i
o
n
)
A
 
p
h
e
n
y
l
a
l
a
n
i
n
e
 
d
e
r
i
v
a
t
i
v
e
1
2
0
 
m
g
 
T
i
D
;
 
6
0
 
m
g
 
T
i
D
,
 
g
i
v
e
 
1
–
3
0
 
m
i
n
u
t
e
s
 
 
p
r
i
o
r
 
t
o
 
e
a
c
h
 
m
e
a
l
∼
0
.
5
–
0
.
8
N
/
A
L
o
w
e
r
 
p
o
t
e
n
t
i
a
l
 
f
o
r
 
 
h
y
p
o
g
l
y
c
e
m
i
a
,
 
b
u
t
 
l
o
w
e
r
 
o
v
e
r
a
l
l
 
 
g
l
u
c
o
s
e
-
l
o
w
e
r
i
n
g
 
e
f
f
e
c
t
i
v
e
n
e
s
s
α
-
G
l
u
c
o
s
i
d
a
s
e
 
i
n
h
i
b
i
t
o
r
s
1
)
 
A
c
a
r
b
o
s
e
 
i
n
h
i
b
i
t
s
 
t
h
e
 
t
e
r
m
i
n
a
l
 
s
t
e
p
 
o
f
 
 
c
a
r
b
o
h
y
d
r
a
t
e
 
d
i
g
e
s
t
i
o
n
 
a
t
 
t
h
e
 
 
b
r
u
s
h
 
b
o
r
d
e
r
 
l
e
v
e
l
 
o
f
 
t
h
e
 
s
m
a
l
l
 
 
i
n
t
e
s
t
i
n
e
 
t
h
e
r
e
b
y
 
s
h
i
f
t
i
n
g
 
a
n
d
 
 
d
e
l
a
y
i
n
g
 
a
b
s
o
r
p
t
i
o
n
 
2
5
 
m
g
–
1
0
0
 
m
g
 
T
i
D
 
p
r
i
o
r
 
t
o
 
e
a
c
h
 
m
e
a
l
 
∼
0
.
4
–
0
.
8
∼
4
.
0
F
l
a
t
u
l
e
n
c
e
,
 
 
a
b
d
o
m
i
n
a
l
 
 
d
i
s
t
r
e
s
s
 
o
r
 
 
d
i
a
r
r
h
e
a
A
G
I
s
 
s
p
e
c
i
fi
c
a
l
l
y
 
h
e
l
p
 
P
P
G
,
 
b
u
t
 
h
a
v
e
 
 
l
i
t
t
l
e
 
e
f
f
e
c
t
 
o
n
 
F
P
G
;
 
c
o
n
t
r
a
i
n
d
i
c
a
t
e
d
 
i
n
 
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
c
h
r
o
n
i
c
 
i
n
t
e
s
t
i
n
a
l
 
 
c
o
n
d
i
t
i
o
n
s
,
 
e
s
p
e
c
i
a
l
l
y
 
i
n
fl
a
m
m
a
t
o
r
y
 
 
b
o
w
e
l
 
d
i
s
e
a
s
e
2
)
 
M
i
g
l
i
t
o
l
 
(
G
l
y
s
e
t
®
,
 
 
B
a
y
e
r
 
H
e
a
l
t
h
C
a
r
e
 
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
s
 
i
n
c
.
)
A
c
a
r
b
o
s
e
 
i
s
 
l
a
r
g
e
l
y
 
u
n
a
b
s
o
r
b
e
d
 
f
r
o
m
 
t
h
e
 
i
n
t
e
s
t
i
n
e
,
 
w
h
e
r
e
a
s
 
 
m
i
g
l
i
t
o
l
 
i
s
 
a
b
s
o
r
b
e
d
 
f
r
o
m
 
t
h
e
 
i
n
t
e
s
t
i
n
e
2
5
 
m
g
–
1
0
0
 
m
g
 
T
i
D
 
p
r
i
o
r
 
t
o
 
e
a
c
h
 
m
e
a
l
G
L
P
-
1
 
a
n
a
l
o
g
s
1
)
 
e
x
e
n
a
t
i
d
e
 
(
B
y
e
t
t
a
®
,
 
 
A
m
y
l
i
n
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
s
,
 
 
i
n
c
.
)
 
T
h
e
 
a
n
a
l
o
g
 
s
i
m
u
l
a
t
e
s
 
t
h
e
 
a
c
t
i
v
i
t
y
 
 
o
f
 
G
L
P
-
1
,
 
n
a
m
e
l
y
 
i
n
s
u
l
i
n
 
s
e
c
r
e
t
i
o
n
 
 
i
n
 
a
 
g
l
u
c
o
s
e
-
d
e
p
e
n
d
e
n
t
 
f
a
s
h
i
o
n
;
 
 
i
n
h
i
b
i
t
s
 
h
y
p
e
r
g
l
u
c
a
g
o
n
e
m
i
a
,
 
s
l
o
w
s
 
 
g
a
s
t
r
i
c
 
e
m
p
t
y
i
n
g
,
 
r
e
d
u
c
e
s
 
a
p
p
e
t
i
t
e
,
 
 
a
n
d
 
i
m
p
r
o
v
e
s
 
s
a
t
i
e
t
y
,
 
p
e
a
k
 
o
f
 
 
a
c
t
i
o
n
 
5
 
µ
g
–
1
0
 
µ
g
 
B
i
D
 
i
n
j
e
c
t
i
o
n
s
 
a
n
y
 
t
i
m
e
 
w
i
t
h
i
n
 
 
6
0
 
m
i
n
u
t
e
s
 
b
e
f
o
r
e
 
m
o
r
n
i
n
g
 
a
n
d
 
e
v
e
n
i
n
g
 
m
e
a
l
s
∼
0
.
5
–
1
.
0
∼
3
.
6
N
a
u
s
e
a
,
 
 
v
o
m
i
t
i
n
g
,
 
 
a
c
u
t
e
 
 
p
a
n
c
r
e
a
t
i
t
i
s
i
n
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
a
 
h
i
s
t
o
r
y
 
o
f
 
 
p
a
n
c
r
e
a
t
i
t
i
s
,
 
o
t
h
e
r
 
d
i
a
b
e
t
i
c
 
a
g
e
n
t
s
 
 
s
h
o
u
l
d
 
b
e
 
c
o
n
s
i
d
e
r
e
d
 
C
a
n
 
b
e
 
u
s
e
d
 
a
s
 
a
d
j
u
n
c
t
 
t
r
e
a
t
m
e
n
t
 
i
n
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
t
y
p
e
 
2
 
d
i
a
b
e
t
e
s
 
w
h
o
 
t
a
k
e
 
m
e
t
f
o
r
m
i
n
,
 
a
 
s
u
l
f
o
n
y
l
u
r
e
a
,
 
o
r
 
a
 
t
h
i
a
z
o
l
i
d
i
n
e
d
i
o
n
e
,
 
o
r
 
w
i
t
h
 
a
 
c
o
m
b
i
n
a
-
t
i
o
n
 
o
f
 
m
e
t
f
o
r
m
i
n
 
a
n
d
 
a
 
s
u
l
f
o
n
y
l
u
r
e
a
 
o
r
 
t
h
i
a
z
o
l
i
d
i
n
e
d
i
o
n
e
.
 
D
e
c
r
e
a
s
e
 
i
n
 
b
o
d
y
 
w
e
i
g
h
t
 
N
o
 
l
o
n
g
-
t
e
r
m
 
s
a
f
e
t
y
 
s
t
u
d
i
e
s
 
a
t
 
t
h
i
s
 
t
i
m
e
 
2
)
 
L
i
r
a
g
l
u
t
i
d
e
 
(
V
i
c
t
o
z
a
®
)
 
N
o
v
o
 
N
o
r
d
i
s
k
1
.
8
 
m
g
 
o
d
 
i
n
j
e
c
t
i
o
n
 
i
n
d
e
p
e
n
d
e
n
t
 
o
f
 
m
e
a
l
s
~
1
.
0
–
1
.
3
c
~
1
.
7
–
2
.
7
c
A
s
 
e
x
e
n
a
t
i
d
e
 
(
a
b
o
v
e
)
A
s
 
e
x
e
n
a
t
i
d
e
 
(
a
b
o
v
e
)
;
 
a
l
s
o
 
u
s
e
 
a
s
 
m
o
n
o
t
h
e
r
a
p
y
;
 
c
o
n
t
r
a
i
n
d
i
c
a
t
e
d
 
i
n
 
M
T
C
 
o
r
 
m
u
l
t
i
p
l
e
 
e
n
d
o
c
r
i
n
e
 
n
e
o
p
l
a
s
i
a
 
s
y
n
d
r
o
m
e
 
t
y
p
e
 
2
(
C
o
n
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n
u
e
d
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A
g
e
n
t
 
M
e
c
h
a
n
i
s
m
 
o
f
 
a
c
t
i
o
n
 
D
o
s
a
g
e
 
H
b
A
1
c
 
r
e
d
u
c
t
i
o
n
,
a
 
%
P
P
G
 
r
e
d
u
c
t
i
o
n
,
 
m
m
o
l
/
L
A
d
v
e
r
s
e
 
e
f
f
e
c
t
s
C
o
m
m
e
n
t
s
/
c
o
n
t
r
a
i
n
d
i
c
a
t
i
o
n
s
 
3
)
 
e
x
e
n
a
t
i
d
e
 
 
s
u
s
t
a
i
n
e
d
 
r
e
l
e
a
s
e
e
x
p
e
c
t
e
d
 
d
u
r
a
t
i
o
n
 
o
f
 
a
c
t
i
o
n
 
 
∼
1
 
w
e
e
k
C
u
r
r
e
n
t
 
s
t
a
t
u
s
:
 
i
n
 
p
h
a
s
e
 
i
i
i
 
 
d
e
v
e
l
o
p
m
e
n
t
D
P
P
-
4
 
i
n
h
i
b
i
t
o
r
s
1
)
 
S
i
t
a
g
l
i
p
t
i
n
 
(
J
a
n
u
v
i
a
®
,
 
 
M
e
r
c
k
 
&
 
C
o
.
,
 
i
n
c
.
)
 
I
n
h
i
b
i
t
s
 
D
P
P
-
4
 
e
n
z
y
m
e
,
 
a
n
d
 
 
t
h
e
r
e
b
y
 
p
r
o
d
u
c
e
s
 
m
o
d
e
r
a
t
e
 
 
i
n
c
r
e
a
s
e
s
 
i
n
 
G
L
P
-
1
 
a
n
d
 
G
i
P
1
0
0
 
m
g
 
o
n
c
e
 
d
a
i
l
y
 
w
i
t
h
 
o
r
 
w
i
t
h
o
u
t
 
f
o
o
d
.
 
 
I
n
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
m
o
d
e
r
a
t
e
 
r
e
n
a
l
 
i
n
s
u
f
fi
c
i
e
n
c
y
 
 
(
C
r
C
L
 

3
0
 
t
o
 

5
0
 
m
L
/
m
i
n
)
 
r
e
d
u
c
e
 
d
o
s
a
g
e
 
 
t
o
 
5
0
 
m
g
 
d
a
i
l
y
.
 
i
n
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
s
e
v
e
r
e
 
r
e
n
a
l
 
 
i
n
s
u
f
fi
c
i
e
n
c
y
 
o
r
 
e
n
d
-
s
t
a
g
e
 
r
e
n
a
l
 
d
i
s
e
a
s
e
 
 
(
C
r
C
L
 
i
s
 

3
0
 
m
L
/
m
i
n
)
 
r
e
d
u
c
e
 
d
o
s
a
g
e
 
 
t
o
 
2
5
 
m
g
 
d
a
i
l
y
∼
0
.
6
–
0
.
8
∼
2
.
8
U
p
p
e
r
 
r
e
s
p
i
r
a
t
o
r
y
 
t
r
a
c
t
 
i
n
f
e
c
t
i
o
n
 
a
n
d
 
n
a
s
o
-
p
h
a
r
y
n
g
i
t
i
s
N
o
 
l
o
n
g
-
t
e
r
m
 
s
a
f
e
t
y
 
s
t
u
d
i
e
s
 
a
t
 
t
h
i
s
 
 
t
i
m
e
 
N
o
 
s
e
r
i
o
u
s
 
a
d
v
e
r
s
e
 
r
e
a
c
t
i
o
n
s
 
 
r
e
p
o
r
t
e
d
 
t
o
 
d
a
t
e
 
w
e
i
g
h
t
 
n
e
u
t
r
a
l
 
 
2
)
 
S
a
x
a
g
l
i
p
t
i
n
 
(
O
n
g
l
y
z
a
™
,
 
B
r
i
s
t
o
l
-
M
y
e
r
s
 
S
q
u
i
b
b
/
A
s
t
r
a
Z
e
n
e
c
a
)
2
.
5
 
m
g
 
o
r
 
5
 
m
g
 
o
n
c
e
 
d
a
i
l
y
 
r
e
g
a
r
d
l
e
s
s
 
o
f
 
 
m
e
a
l
s
 
2
.
5
 
m
g
 
i
s
 
r
e
c
o
m
m
e
n
d
e
d
 
f
o
r
 
p
a
t
i
e
n
t
s
 
 
w
i
t
h
 
m
o
d
e
r
a
t
e
 
o
r
 
s
e
v
e
r
e
 
r
e
n
a
l
 
i
m
p
a
i
r
m
e
n
t
,
 
 
o
r
 
e
n
d
-
s
t
a
g
e
 
r
e
n
a
l
 
d
i
s
e
a
s
e
 
(
C
r
C
L
 

5
0
 
m
L
/
m
i
n
)
.
 
 
2
.
5
 
m
g
 
i
s
 
r
e
c
o
m
m
e
n
d
e
d
 
f
o
r
 
p
a
t
i
e
n
t
s
 
a
l
s
o
 
t
a
k
i
n
g
 
s
t
r
o
n
g
 
c
y
t
o
c
h
r
o
m
e
 
P
4
5
0
 
3
A
4
/
5
 
i
n
h
i
b
i
t
o
r
s
A
s
 
s
i
t
a
g
l
i
p
t
i
n
 
(
a
b
o
v
e
)
A
s
 
s
i
t
a
g
l
i
p
t
i
n
 
(
a
b
o
v
e
)
A
s
 
s
i
t
a
g
l
i
p
t
i
n
 
(
a
b
o
v
e
)
A
s
 
s
i
t
a
g
l
i
p
t
i
n
 
(
a
b
o
v
e
)
3
)
 
V
i
l
d
a
g
l
i
p
t
i
n
 
5
0
 
m
g
 
B
i
D
,
 
m
a
x
 
1
0
0
 
m
g
 
C
u
r
r
e
n
t
 
s
t
a
t
u
s
:
 
a
p
p
r
o
v
e
d
 
i
n
 
e
u
r
o
p
e
 
4
)
 
A
l
o
g
l
i
p
t
i
n
 
N
/
A
 
C
u
r
r
e
n
t
 
s
t
a
t
u
s
:
 
u
n
d
e
r
 
F
D
A
 
r
e
v
i
e
w
R
a
p
i
d
-
a
c
t
i
n
g
 
i
n
s
u
l
i
n
s
1
)
 
L
i
s
p
r
o
 
(
H
u
m
a
l
o
g
®
,
 
 
e
l
i
 
L
i
l
l
y
 
a
n
d
 
C
o
m
p
a
n
y
)
 
S
u
p
p
r
e
s
s
e
s
 
g
l
u
c
o
s
e
 
p
r
o
d
u
c
t
i
o
n
 
 
a
n
d
 
i
n
c
r
e
a
s
e
s
 
e
f
fi
c
i
e
n
c
y
 
o
f
 
t
i
s
s
u
e
 
 
g
l
u
c
o
s
e
 
u
p
t
a
k
e
I
n
d
i
v
i
d
u
a
l
i
z
e
d
V
a
r
i
a
b
l
e
 
 
d
e
p
e
n
d
i
n
g
 
o
n
 
 
a
g
g
r
e
s
s
i
v
e
n
e
s
s
 
 
o
f
 
t
i
t
r
a
t
i
o
n
∼
1
1
 
(
n
o
t
 
P
B
O
 
 
c
o
r
r
e
c
t
e
d
)
b
H
y
p
o
g
l
y
c
e
m
i
a
 
 
a
n
d
 
w
e
i
g
h
t
 
 
g
a
i
n
2
)
 
A
s
p
a
r
t
 
(
N
o
v
o
L
o
g
®
,
 
 
N
o
v
o
 
N
o
r
d
i
s
k
)
 
N
/
A
 
3
)
 
G
l
u
l
i
s
i
n
e
 
(
A
p
i
d
r
a
®
,
 
 
s
a
n
o
fi
-
a
v
e
n
t
i
s
 
U
S
 
L
L
C
)
N
/
A
 
v
s
 
P
B
O
a
A
s
s
u
m
i
n
g
 
a
n
 
i
n
i
t
i
a
l
 
H
b
A
1
c
 
o
f
 
a
t
 
l
e
a
s
t
 
8
%
.
b
L
i
s
p
r
o
 
(
H
u
m
a
l
o
g
®
,
 
e
l
i
 
L
i
l
l
y
 
a
n
d
 
C
o
m
p
a
n
y
)
.
c
e
x
e
n
a
t
i
d
e
 
a
n
d
 
l
i
r
a
g
l
u
t
i
d
e
 
H
b
A
1
c
 
e
f
fi
c
a
c
y
 
b
a
s
e
d
 
o
n
 
c
o
m
b
i
n
a
t
i
o
n
 
t
h
e
r
a
p
y
.
D
a
t
a
 
o
b
t
a
i
n
e
d
 
f
r
o
m
 
e
a
c
h
 
p
r
o
d
u
c
t
’
s
 
r
e
s
p
e
c
t
i
v
e
 
p
a
c
k
a
g
e
 
i
n
s
e
r
t
 
a
n
d
 
N
a
t
h
a
n
 
D
M
 
e
t
 
a
l
.
6
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
A
G
i
,
 
α
-
g
l
u
c
o
s
i
d
a
s
e
 
i
n
h
i
b
i
t
o
r
;
 
B
i
D
,
 
t
w
i
c
e
 
d
a
i
l
y
;
 
C
r
C
L
,
 
c
r
e
a
t
i
n
i
n
e
 
c
l
e
a
r
a
n
c
e
;
 
D
P
P
-
4
,
 
d
i
p
e
p
t
i
d
y
l
 
p
e
p
t
i
d
a
s
e
-
4
;
 
F
P
G
,
 
f
a
s
t
i
n
g
 
p
l
a
s
m
a
 
g
l
u
c
o
s
e
;
 
G
i
P
,
 
g
l
u
c
o
s
e
-
d
e
p
e
n
d
e
n
t
 
i
n
s
u
l
i
n
o
t
r
o
p
i
c
 
p
o
l
y
p
e
p
t
i
d
e
;
 
G
L
P
-
1
,
 
g
l
u
c
a
g
o
n
-
l
i
k
e
 
p
e
p
t
i
d
e
-
1
;
 
 
K
A
T
P
,
 
p
o
t
a
s
s
i
u
m
 
a
d
e
n
o
s
i
n
e
 
t
r
i
p
h
o
s
p
h
a
t
e
;
 
M
T
C
,
 
m
e
d
u
l
l
a
r
y
 
t
h
y
r
o
i
d
 
c
a
r
c
i
n
o
m
a
;
 
P
B
O
,
 
p
l
a
c
e
b
o
;
 
P
P
G
,
 
p
o
s
t
p
r
a
n
d
i
a
l
 
g
l
u
c
o
s
e
;
 
S
U
R
,
 
s
u
l
f
o
n
y
l
u
r
e
a
 
r
e
c
e
p
t
o
r
;
 
T
i
D
,
 
3
 
t
i
m
e
s
 
d
a
i
l
y
.
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GLP-1 analogs
Endogenous GLP-1 is rapidly cleared (1–2 minutes) by the 
enzyme DPP-4; therefore, the natural form is not practical as 
a therapeutic intervention in type 2 diabetes management.56 
Injectable GLP-1 analogs are resistant to DPP-4 and thus, have 
a longer half-life than endogenous GLP-1. GLP-1 analogs 
increase glucose-dependent insulin secretion and decrease 
glucagon secretion, leading to PPG control, delayed gastric 
emptying, and increased satiety, potentially leading to weight 
loss. Exenatide (Byetta®, Amylin Pharmaceuticals, Inc.) and 
liraglutide (Victoza®; Novo Nordisk) are injected twice daily 
and once daily, respectively. Their use in combination lowers 
HbA1c by approximately 0.5% to 1.0%.6,57 Both agents are 
approved for use in combination with metformin, a sulfonyl-
urea (SU), and/or a thiazolidinedione (TZD); liraglutide is also 
available as monotherapy in the United States.6,57 Both agents 
are associated with gastrointestinal (GI) side effects, including 
diarrhea, vomiting, and nausea and there is also an associa-
tion with acute pancreatitis.6,57 Therefore, the Food and Drug 
Administration recommends that in a patient with diabetes who 
has a history of pancreatitis, other antidiabetic agents should be 
considered.57,58 For liraglutide, the US prescribing information 
includes a boxed warning for the risk of thyroid C-cell tumors.57 
A sustained-release form of exenatide, with duration of up to 
one week is currently in late-phase development.59,60 
DPP-4 inhibitors
The DPP-4 inhibitors sitagliptin and saxagliptin were approved 
in 2006 and 2009, respectively. Vildagliptin, another DPP-4 
inhibitor, is currently approved outside the United States. DPP-
4 inhibitors, like GLP-1 analogs, mechanistically decrease PPG 
and have a low propensity for hypoglycemia or weight gain.61–63 
Alogliptin, dutogliptin, and linagliptin are other DPP-4 inhibi-
tors in various stages of development. These DPP-4 inhibitors 
have been studied as monotherapy as well as in combination 
with metformin, SUs, and TZDs. DPP-4 inhibitors have fewer 
GI side effects than GLP-1 analogs.61,63
Rapid-acting insulins
Rapid-acting insulins (lispro, aspart, or glulisine) improve PPG 
when administered before a meal.29,64,65 An alternative would be 
pre-breakfast and pre-dinner premix insulins containing a rapid-
acting insulin and a long-acting insulin.66 These latter insulin regi-
mens, however, are less flexible and are associated with greater 
risk of hypoglycemia than rapid-acting insulin regimens.66
Guideline update
In 2009, the AACE released a new treatment algorithm. 
While there were no changes to the placement of insulin in 
the algorithm (ie, last line of therapy after oral antidiabetic 
drug use), the new recommendations advocate the early 
use of the incretin-based therapies GLP-1 analogues and 
DPP-4 inhibitors.67 More specifically, incretin-based thera-
pies are recommended as monotherapy for patients with 
HbA1c 6.5% to 7.5%, which most closely corresponds to the 
HbA1c range previously identified to be most impacted by 
PPG targeting.7,28
Conclusions
Substantial evidence has accumulated indicating that chronic 
hyperglycemia is a risk factor for micro- and macrovascular 
disease. Observational studies indicate that isolated post-
prandial hyperglycemia increases CV mortality. Various 
antihyperglycemic agents now exist that preferentially tar-
get postprandial hyperglycemia (meglitinides, rapid-acting 
insulin analogs, GLP-1 agonists, and DPP-4 inhibitors) and 
afford physicians a choice of treatment options that can 
now be based on individual patient profiles. Controlling 
and achieving target goals early in the course of diabetes 
has been shown to provide better outcomes in terms of CV 
risk. Postprandial glucose should be normalized along with 
FPG to achieve the currently recommended goal of HbA1c 
7%. As reflected in recent trials, a less intense goal may be 
needed for certain subpopulations of patients with diabetes 
who have a history of severe CVD, severe hypoglycemia, 
advanced age, or advanced microvascular or macrovascular 
complications. Target levels of glucose control should be 
individualized by focusing on both FPG and PPG and by 
optimizing other risk factors of CVD, including high blood 
pressure, hyperlipidemia, obesity, smoking, and poor exercise 
and dietary habits.
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